Top

Published in:

01-02-2010 | Pancreatic Tumors

Preoperative Diabetes Mellitus and Long-Term Survival After Resection of Pancreatic Adenocarcinoma

Authors: Carrie K. Chu, MD, Ashley E. Mazo, BS, Michael Goodman, MD, MPH, Vasili Egnatashvili, MD, Juan M. Sarmiento, MD, Charles A. Staley, MD, John R. Galloway, MD, N. Volkan Adsay, MD, Sol Jacobs, MD, David A. Kooby, MD

Published in: Annals of Surgical Oncology | Issue 2/2010

Abstract

Purpose

To assess clinicopathologic features and postresection survival of diabetes mellitus (DM)-associated pancreatic ductal adenocarcinoma (PDAC).

Methods

Records of resected PDAC patients from 2000 to 2007 were reviewed. DM was classified as new-onset (<24 months before PDAC) or longstanding (≥24 months). Clinicopathologic features were compared by univariate and multivariate analyses. Survival was assessed by Kaplan–Meier method and Cox regression.

Results

Of 209 patients, 93 (45%) met criteria for DM (35 longstanding DM, 55 new-onset DM, 3 duration unknown). DM patients were older (DM 66 ± 9 years, non-DM 63 ± 12 years, P = 0.06); a majority had additional preoperative comorbidities (DM 64.5%, non-DM 25.9%, P < 0.001). Tumor size was larger in patients with DM (DM 3.8 ± 1.7 cm, non-DM 3.2 ± 1.5 cm, P = 0.003). Groups were similar in terms of tumor location, perineural/lymphovascular invasion, and node and margin status. On logistic regression, tumor size ≥3.0 cm was independently associated with both overall DM (odds ratio [OR] 3.60; 95% confidence interval [1.79–7.26]) and new-onset DM (OR 3.69, [1.65–8.24]). Median survival was reduced in patients with DM compared with non-DM (15 versus 17 months, P = 0.015). Multivariate analysis controlling for prognostic variables including age, comorbidities, and tumor size demonstrated that DM was independently associated with reduced survival (hazard ratio [HR] 1.55, [1.02–2.35]). This association was more pronounced for patients with new-onset DM (HR 1.75 [1.10–2.78]) than those with longstanding DM (HR 1.30 [0.75–2.25]).

Conclusions

Preexisting DM is associated with reduced survival in patients undergoing resection for PDAC. PDAC with new-onset DM may exhibit increased tumor size and decreased postresection survival. Additional investigation is needed to clarify etiology and impact of PDAC-associated DM.

Bright R. Cases and observations connected with disease of the pancreas and duodenum. Med Chir Trans. 1833;18:1-56.

American Cancer Society: Cancer Facts and Figures 2008. http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_pancreatic_cancer_34.asp?sitearea=. Accessed February 11, 2009.

Centers for Disease Control and Prevention: National Diabetes Fact Sheet, 2007. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf. Accessed February 12, 2009.

King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414–31.

Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.CrossRefPubMed

Pannala R, Leirness JB, Bamlet WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134(4):981–7.CrossRefPubMed

Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134(1):95–101.CrossRefPubMed

Wynder EL, Mabuchi K, Maruchi N, Fortner JG. Epidemiology of cancer of the pancreas. J Natl Cancer Inst. 1973;50(3):645–67.PubMed

Hiatt RA, Klatsky AL, Armstrong MA. Pancreatic cancer, blood glucose and beverage consumption. Int J Cancer. 1988;41(6):794–7.CrossRefPubMed

10.

Kalapothaki V, Tzonou A, Hsieh CC, et al. Tobacco, ethanol, coffee, pancreatitis, diabetes mellitus, and cholelithiasis as risk factors for pancreatic carcinoma. Cancer Causes Control. 1993;4(4):375–82.CrossRefPubMed

11.

Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer. 2007;96(3):507–9.CrossRefPubMed

12.

Batty GD, Kivimaki M, Morrison D, et al. Risk factors for pancreatic cancer mortality: extended follow-up of the original Whitehall study. Cancer Epidemiol Biomarkers Prev. 2009.

13.

Ansary-Moghaddam A, Huxley R, Barzi F, et al. The effect of modifiable risk factors on pancreatic cancer mortality in populations of the Asia-Pacific region. Cancer Epidemiol Biomarkers Prev. 2006;15(12):2435–40.CrossRefPubMed

14.

Calle EE, Murphy TK, Rodriguez C, et al. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control. 1998;9(4):403–10.CrossRefPubMed

15.

Gullo L, Pezzilli R, Morselli-Labate AM. Diabetes and the risk of pancreatic cancer. N Engl J Med. 1994;331(2):81–4.CrossRefPubMed

16.

Wang F, Gupta S, Holly EA. Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiol Biomarkers Prev. 2006;15(8):1458–63.CrossRefPubMed

17.

Permert J, Ihse I, Jorfeldt L, et al. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg. 1993;80(8):1047–50.CrossRefPubMed

18.

Basso D, Plebani M, Fogar P, et al. Beta-cell function in pancreatic adenocarcinoma. Pancreas. 1994;9(3):332–5.CrossRefPubMed

19.

Litwin J, Dobrowolski S, Orlowska-Kunikowska E, Sledzinski Z. Changes in glucose metabolism after Kausch-Whipple pancreatectomy in pancreatic cancer and chronic pancreatitis patients. Pancreas. 2008;36(1):26–30.CrossRefPubMed

20.

Bell RH Jr, Place S, McCullough P, et al. Pancreatic insulin secretion in exocrine pancreatic cancer. J Surg Res. 1986;40(6):588–96.CrossRefPubMed

21.

Liu J, Knezetic JA, Strommer L, et al. The intracellular mechanism of insulin resistance in pancreatic cancer patients. J Clin Endocrinol Metab. 2000;85(3):1232–8.CrossRefPubMed

22.

Fogar P, Basso D, Panozzo MP, et al. C-peptide pattern in patients with pancreatic cancer. Anticancer Res. 1993;13(6):2577–80.PubMed

23.

Gullo L, Ancona D, Pezzilli R, et al. Glucose tolerance and insulin secretion in pancreatic cancer. Ital J Gastroenterol. 1993;25(9):487–9.PubMed

24.

Stolzenberg-Solomon RZ, Graubard BI, Chari S, et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA. 2005;294(22):2872–8.CrossRefPubMed

25.

Permert J, Adrian TE, Jacobsson P, et al. Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor? Am J Surg. 1993;165(1):61–6; discussion 66–7.

26.

Basso D, Brigato L, Veronesi A, et al. The pancreatic cancer cell line MIA PaCa2 produces one or more factors able to induce hyperglycemia in SCID mice. Anticancer Res. 1995;15(6):2585–8.PubMed

27.

Basso D, Greco E, Fogar P, et al. Pancreatic cancer-derived S-100A8 N-terminal peptide: a diabetes cause? Clin Chim Acta. 2006;372(1–2):120–8.CrossRefPubMed

28.

Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300(23):2754–64.CrossRefPubMed

29.

van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, et al. Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer. 2007;120(9):1986–92.CrossRefPubMed

30.

Park SM, Lim MK, Shin SA, Yun YH. Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol. 2006;24(31):5017–24.CrossRefPubMed

31.

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMed

32.

Social Security Death Index, RootsWeb 2009. http://ssdi.rootsweb.ancestry.com/. accessed February 16, 2009.

33.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(Suppl 1):S62–7.CrossRef

34.

Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567–79.CrossRefPubMed

35.

Garcea G, Dennison AR, Pattenden CJ, et al 2008 Survival following curative resection for pancreatic ductal adenocarcinoma A systematic review of the literature. JOP. 9(2):99–132.PubMed

36.

Kleinbaum D, Klein M. Logistic regression: a self-learning text. New York: Springer; 2002.

37.

Valerio A, Basso D, Mazza S, et al. Serum protein profiles of patients with pancreatic cancer and chronic pancreatitis: searching for a diagnostic protein pattern. Rapid Commun Mass Spectrom. 2001;15(24):2420–5.CrossRefPubMed

38.

Basso D, Millino C, Greco E, et al. Altered glucose metabolism and proteolysis in pancreatic cancer cell conditioned myoblasts: searching for a gene expression pattern with a microarray analysis of 5000 skeletal muscle genes. Gut. 2004;53(8):1159–66.CrossRefPubMed

39.

Basso D, Greco E, Fogar P, et al. Pancreatic cancer-associated diabetes mellitus: an open field for proteomic applications. Clin Chim Acta. 2005;357(2):184–9.CrossRefPubMed

40.

Meggiato T, Plebani M, Basso D, et al. Serum growth factors in patients with pancreatic cancer. Tumour Biol. 1999;20(2):65–71.CrossRefPubMed

41.

Isaksson B, Strommer L, Friess H, et al. Impaired insulin action on phosphatidylinositol 3-kinase activity and glucose transport in skeletal muscle of pancreatic cancer patients. Pancreas. 2003;26(2):173–7.CrossRefPubMed

42.

Fogar P, Pasquali C, Basso D, et al. Diabetes mellitus in pancreatic cancer follow-up. Anticancer Res. 1994;14(6):2827–30.PubMed

43.

Ishikawa O, Ohhigashi H, Wada A, et al. Morphologic characteristics of pancreatic carcinoma with diabetes mellitus. Cancer. 1989;64(5):1107–12.CrossRefPubMed

44.

Fisher WE, McCullough PJ, Ray MB, et al. Diabetes enhances growth of pancreatic carcinoma cells. Surgery. 1988;104(2):431–6.PubMed

45.

Fisher WE, Boros LG, Schirmer WJ. Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. J Surg Res. 1996;63(1):310–3.CrossRefPubMed

46.

Fisher WE, Muscarella P, Boros LG, Schirmer WJ. Variable effect of streptozotocin-diabetes on the growth of hamster pancreatic cancer (H2T) in the Syrian hamster and nude mouse. Surgery. 1998;123(3):315–20.PubMed

47.

Stoeltzing O, Liu W, Fan F, et al. Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system. Cancer Lett. 2007;258(2):291–300.CrossRefPubMed

48.

Bergmann U, Funatomi H, Yokoyama M, et al. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 1995;55(10):2007–11.PubMed

49.

Ding X, Flatt PR, Permert J, Adrian TE. Pancreatic cancer cells selectively stimulate islet beta cells to secrete amylin. Gastroenterology. 1998;114(1):130–8.CrossRefPubMed

50.

Ganti AK, Potti A, Koch M, et al. Predictive value of clinical features at initial presentation in pancreatic adenocarcinoma: a series of 308 cases. Med Oncol. 2002;19(4):233–7.CrossRefPubMed

51.

Talar-Wojnarowska R, Gasiorowska A, Strzelczyk J, et al. Prognostic factors in the operative and palliative treatment of pancreatic cancer. Neoplasma. 2003;50(5):383–7.PubMed

52.

Wakasugi H, Funakoshi A, Iguchi H. Clinical observations of pancreatic diabetes caused by pancreatic carcinoma, and survival period. Int J Clin Oncol. 2001;6(1):50–4.CrossRefPubMed

53.

Coughlin SS, Calle EE, Patel AV, Thun MJ. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control. 2000;11(10):915–23.CrossRefPubMed

54.

Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007;110(4):738–44.CrossRefPubMed

55.

Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg. 1996;83(5):625–31.CrossRefPubMed

56.

Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10(1):88–95.CrossRefPubMed

Title: Preoperative Diabetes Mellitus and Long-Term Survival After Resection of Pancreatic Adenocarcinoma
Authors: Carrie K. Chu, MD
Ashley E. Mazo, BS
Michael Goodman, MD, MPH
Vasili Egnatashvili, MD
Juan M. Sarmiento, MD
Charles A. Staley, MD
John R. Galloway, MD
N. Volkan Adsay, MD
Sol Jacobs, MD
David A. Kooby, MD
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 2/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-009-0789-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Preoperative Diabetes Mellitus and Long-Term Survival After Resection of Pancreatic Adenocarcinoma

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2010

Renal Cell Carcinoma and Prognostic Factors Predictive of Survival

Why Does No One Want to Perform Lymph Node Dissection Anymore?

Mini-Mesohepatectomy for Colorectal Metastasis Invading the Middle Hepatic Vein at the Hepatocaval Confluence: Educational Video Demonstrating IOUS Use in Modern Hepatic Surgery

Cytoreductive Surgery in Patients with Metastatic Gastrointestinal Stromal Tumor Treated with Sunitinib Malate

Stage III Colorectal Cancer: Molecular Disparity Between Primary Cancers and Lymph Node Metastases

E2F1 Expression Predicts Outcome in Korean Women Who Undergo Surgery for Breast Carcinoma